Sun Pharma Advanced Research Company Share Price

SPARC

CMP as on 20-Oct-21 15:53

₹ 280.50
-12.45 -4.25%

Open

₹ 291.10

Turnover (lac)

₹ 1,712

Prev. Close

₹ 292.95

Day's Vol (shares)

₹ 6,10,508

Day's Range (₹)

₹ 277.05
₹ 292.80

CMP as on20-Oct-21 15:50

₹ 280.30
-12.25 -4.19%

Open

₹ 292.10

Turnover (lac)

₹ 327

Prev. Close

₹ 292.55

Day's Vol (shares)

₹ 66,252

Day's Range

₹ 277.30
₹ 292.90

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 29-Aug-2021 - -
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2021 ,inter alia, to consider and approve / evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. As per letter attached (As Per BSE Announcement dated on 01.09.2021)
Board Meeting - 17-Jul-2021 - -
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Monday, July 26, 2021, to inter alia consider and approve, the unaudited financial results of the Company for the quarter ended June 30, 2021. Further, kindly note that pursuant to the Companys Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of financial results of the Company on July 26, 2021. As per letter attached (As Per BSE Announcement dated on 26.07.2021)
Board Meeting - 25-May-2021 - -
Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Board of Directors of the Company at their meeting held 04:30 pm to 08:00 pm today, inter alia, took the following decisions: i.Mr. Dilip Shanghvi expressed his desire to step down and tendered his resignation asthe Managing Director of the Company with immediate effect, which was accepted bythe Board as recommended by the Nomination & Remuneration Committee. Mr. DilipShanghvi will continue to be associated with the Board in his capacity as a non-executive director and Chairman of the Company.ii.On recommendation of Nomination and Remuneration Committee, the Board hasappointed Mr. Anil Raghavan, as a Chief Executive Officer (CEO) and whole time keymanagerial personnel of the Company with immediate effect, for a term of five yearsi.e upto 24th May 2026, subject to approval of members in a General Meeting of theCompany. In view of various queries received by us consequent to our letter to stock exchange bearing no. SPARC/Sec/SE/2021-22/016 dated 25th May 2021 on Outcome of Board Meeting held on 25th May 2021, it is clarified that Mr. Dilip Shanghvi has voluntarily chosen to step down as the Managing Director of the Company, inter alia, as a measure of good corporate governance and to proactively comply with the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates separation of the role of Chairman & Managing Director/ Manager of the Company with effect from 1st April 2022.
Board Meeting - 09-May-2021 - -
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2021 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 17th May 2021, inter alia, to consider and approve, the audited financial results of the Company for the quarter and financial year ended 31st March 2021. Further, kindly note that pursuant to the Companys Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of financial results of the Company on 17th May 2021. The Board of Directors of the Company at their meeting held from 06:00 pm to 09:15 pm today, inter alia, took the following decisions: i. Took on record and duly approved the Audited Financial Results of the Company for the quarter and year ended 31st March 2021 which is enclosed herewith along with the Auditors Report on the Financial Statements of the Company for the Financial Year ended 31st March 2021 as Annexure 1. In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2021 is also enclosed as Annexure 2. ii. Accepted the resignation of Mr. Debashis Dey as the Company Secretary and Compliance Officer of the Company after the end of working hours on Friday, 25th June 2021. This is for your information and record. The Board of Directors of the Company at their meeting held from 06:00 pm to 09:15 pm today, inter alia, took the following decisions: i. Took on record and duly approved the Audited Financial Results of the Company for the quarter and year ended 31st March 2021 which is enclosed herewith along with the Auditors Report on the Financial Statements of the Company for the Financial Year ended 31st March 2021 as Annexure 1. In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2021 is also enclosed as Annexure 2. ii. Accepted the resignation of Mr. Debashis Dey as the Company Secretary and Compliance Officer of the Company after the end of working hours on Friday, 25th June 2021. This is for your information and record. (AS Per BSE Announcement Dated on 17.05.2021)
Board Meeting - 09-May-2021 - -
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2021 ,inter alia, to consider and approve Pursuant to regulation 29 (1) (d) of the SEBI (LODR) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Wednesday, 12th May 2021, inter alia, to consider and evaluate proposals for raising of funds in one or more tranches by way of issue of Equity Shares or Securities/ Warrants convertible into Equity shares of the Company, through permissible modes including by way of Preferential Issue, subject to the receipt of necessary approvals. Outcome of Board Meeting pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Kindly refer to attached letter (AS Per BSE Announcement Dated on 12.05.2021) Please refer to our earlier letter no. SPARC/Sec/SE/2021-22/13 dated 12th May 2021 on Outcome of Board Meeting held on 12th May 2021. You are requested to take on record following inadvertent errors/ corrections required in Annexure 1 to above referred letter: 1. The name of the entity mentioned at Sr. no. 8 should be read as Cohesion MK Best Ideas Sub-Trust instead of Cohesion Investment (Cayman) Limited. 2. The name of the entities mentioned at Sr. no. 25 and 26 needs to be inter-changed i.e. Sr. No. 25 should be read as The TIFF Keystone Fund, L.P instead of Catholic Endowment Fund, L.P.. and Sr. No. 26 should be read as Catholic Endowment Fund, L.P.. instead of The TIFF Keystone Fund, L.P (AS Per BSE Announcement Dated on 14.05.2021)
Board Meeting - 29-Jan-2021 - -
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2021 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 8th February 2021, inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter ended 31st December 2020. Further, kindly note that pursuant to the Companys Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of financial results of the Company on 8th February 2021. The Board of Directors of the Company at their meeting held from 07:00 pm to 09:15 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 31st December 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I. (As per BSE Announcement Dated on 8/2/2021)
Board Meeting - 30-Oct-2020 - -
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2020 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 9th November 2020, inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter and six months ended 30th September 2020. Further, kindly note that pursuant to the Companys Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of financial results of the Company on 9th November 2020. This is for your information and record. The Board of Directors of the Company at their meeting held from 07:00 pm to 08:15 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 30th September 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I. This is for your information and record. Thanking you, Yours faithfully, (As per BSE Announcement Dated on 09/11/2020)
Open ZERO Brokerage Demat Account